igmbio.com Open in urlscan Pro
141.193.213.11  Public Scan

Form analysis
0 forms found in the DOM

Text Content

Skip to content

IGM Biosciences

 * About Us
   * Our Company
   * Leadership Team
 * IGM Platform
   * Our IGM Platform
   * Publications
   * Presentations
 * Pipeline & Programs
   * Pipeline
   * Aplitabart
   * Imvotamab
   * IGM-2644
 * Investors & News
 * Join Us
   * Our Culture
   * Open Jobs
 * Contact Us


REIMAGINING
antibody medicines
REIMAGINING
antibody medicines
REIMAGINING
antibody medicines
REIMAGINING
antibody medicines
REIMAGINING
antibody medicines
‹›


IGM Biosciences is pioneering a new class of antibody medicines for the
treatment of cancer and autoimmune and inflammatory diseases. Building upon the
greater binding power provided by the naturally occurring IgM antibody
structure, as compared with the commonly used IgG antibody structure, IGM has
been able to create “super antibodies” with the potential to generate novel
therapeutic options and hope for patients.

» LEARN MORE ABOUT WHAT SETS US APART




REIMAGINING ANTIBODY MEDICINES

We believe we have the world’s most advanced research and development program
focused on engineered therapeutic IgM antibodies.

Using our expertise to expand upon and improve the inherent qualities of IgM
antibodies and produce them at scale, we aim to develop a range of therapeutic
antibodies for the treatment of cancer and autoimmune and inflammatory diseases.

» READ MORE ABOUT OUR PLATFORM





EXPLORING SCIENTIFIC BOUNDARIES

By developing this new class of antibodies,
we have opened up new approaches to treating disease.

» Learn more about our lead programs





MAKE AN IMPACT AT IGM

Help us bring a new class of antibody medicines to patients.

» LEARN MORE ABOUT BEING PART OF THE IGM TEAM





RECENT NEWS

May 29, 2024
IGM Biosciences to Present at the Jefferies Healthcare Conference
May 8, 2024
IGM Biosciences Announces First Quarter 2024 Financial Results and Provides
Corporate Update
May 7, 2024
IGM Biosciences to Present at the 2024 RBCCM Global Healthcare Conference
April 17, 2024
IGM Biosciences Announces Refocusing of Sanofi Collaboration
April 10, 2024
IGM Biosciences to Present at the Stifel 2024 Virtual Targeted Oncology Forum


FEATURED

Presentations at the 2024 American Association for Cancer Research Annual
Meeting

AACR 2024 Presentations 

IGM-2644, a Novel CD38xCD3 Bispecific IgM T Cell Engager Demonstrates Potent
Efficacy on Myeloma Cells with an Improved Preclinical Safety Profile

64th American Society of Hematology (ASH) Annual Meeting and Exposition —
December 10-13, 2022

Pharmacodynamics and Biomarker Correlates of Imvotamab (IGM-2323), the
First-In-Class CD20xCD3 Bispecific IGM Antibody with Dual Mechanisms of Action,
in Patients with Advanced B Cell Malignancies

64th American Society of Hematology (ASH) Annual Meeting and Exposition —
December 10-13, 2022

 






All content © IGM Biosciences, Inc.      info@igmbio.com      Privacy Policy   
  Terms of Use  Site Credits